» Articles » PMID: 14660435

Hedgehog and PI-3 Kinase Signaling Converge on Nmyc1 to Promote Cell Cycle Progression in Cerebellar Neuronal Precursors

Overview
Journal Development
Specialty Biology
Date 2003 Dec 9
PMID 14660435
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Neuronal precursor cells in the developing cerebellum require activity of the sonic hedgehog (Shh) and phosphoinositide-3-kinase (PI3K) pathways for growth and survival. Synergy between the Shh and PI3K signaling pathways are implicated in the cerebellar tumor medulloblastoma. Here, we describe a mechanism through which these disparate signaling pathways cooperate to promote proliferation of cerebellar granule neuron precursors. Shh signaling drives expression of mRNA encoding the Nmyc1 oncoprotein (previously N-myc), which is essential for expansion of cerebellar granule neuron precursors. The PI3K pathway stabilizes Nmyc1 protein via inhibition of GSK3-dependent Nmyc1 phosphorylation and degradation. The effects of PI3K activity on Nmyc1 stabilization are mimicked by insulin-like growth factor, a PI3K agonist with roles in central nervous system precursor growth and tumorigenesis. These findings indicate that Shh and PI3K signaling pathways converge on N-Myc to regulate neuronal precursor cell cycle progression. Furthermore, they provide a rationale for therapeutic targeting of PI3K signaling in medulloblastoma.

Citing Articles

Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?.

Wang W, Du Y, Datta S, Fowler J, Sang H, Albadari N Genes Dis. 2025; 12(2):101156.

PMID: 39802403 PMC: 11719324. DOI: 10.1016/j.gendis.2023.101156.


SHH medulloblastoma and very early onset of bowel polyps in a child with hamartoma tumor syndrome.

Caroleo A, Rotulo S, Agolini E, Macchiaiolo M, Boccuto L, Antonelli M Front Mol Neurosci. 2023; 16:1228389.

PMID: 37692099 PMC: 10483120. DOI: 10.3389/fnmol.2023.1228389.


The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia.

Wu A, Turner K, Woolfson A, Jiang X Pharmaceutics. 2023; 15(3).

PMID: 36986819 PMC: 10053130. DOI: 10.3390/pharmaceutics15030958.


MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.

Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P Cancers (Basel). 2022; 14(18).

PMID: 36139583 PMC: 9496712. DOI: 10.3390/cancers14184421.


A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.

Elhasasna H, Khan R, Bhanumathy K, Vizeacoumar F, Walke P, Bautista M Cells. 2022; 11(14).

PMID: 35883689 PMC: 9317991. DOI: 10.3390/cells11142246.